Harrow, Inc. (NASDAQ: HROW - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company.
Squarepoint Ops LLC decreased its position in Harrow, Inc. (NASDAQ: HROW) by 77.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,956 shares of the company's stock after selling 73,294 shares during the quarter. Squarepoint Ops LLC owned approximately
Biotech stock Harrow is in a cup base with a buy point of 50.72 after third-quarter results.
Harrow, Inc. is experiencing explosive growth, driven by its success in branded pharmaceuticals, especially Vevye. Vevye, HROW's flagship dry eye drug, is projected to reach $100M in 2025 and $300M in 2026, with potential for $2B+ by 2030. HROW's financials are accelerating: FCF/share expected at $4 in 2026 and $10 in 2027, with leverage rapidly declining and EBITDA margins rising.
Geode Capital Management LLC raised its stake in shares of Harrow, Inc. (NASDAQ: HROW) by 4.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 810,803 shares of the company's stock after acquiring an additional 36,724 shares during the period.
Philadelphia-based Penn Capital Management added 325,478 shares of Harrow for an estimated $15.7 million in the third quarter. The move created a new position for Penn, which did not report holding any shares of Harrow in the previous quarter.
NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5 th Annual Ophthalmology Day (Virtual) Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37 th Annual Healthcare Conference (New York, NY) Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3:00 PM EST The fireside chat at Piper Sandler will be webcast live and can be found on the Event's page on the Company's website.
NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt's product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolving tablet) drug delivery platform. The closing of the Melt acquisition marks a strategic expansion of Harrow's portfolio and reinforces its commitment to delivering innovative therapies that improve patient outcomes.
Insights from Private Capital (Trades, Portfolio)'s Third Quarter 2025 13F Filing Private Capital (Trades, Portfolio) recently submitted its 13F filing for the
Harrow, Inc. ( HROW ) Q3 2025 Earnings Call November 11, 2025 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO & Corporate Secretary Patrick Sullivan - Head of Commercial Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Thomas Shrader - BTIG, LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C.
